Inventor · disambiguated record
Uchenna H. Iloeje
Also filed as: ILOEJE UCHENNA H
14 granted patents·9 pending applications·42 citations·filing 2023–2025
92Inventor score
Files withSPRINGWORKS THERAPEUTICS INC23
Top patents by PatentIndex Score
23 records- 0197US12011424B2Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jun 18, 2024·4 cites·6 claims
- 0297US11819487B2Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 21, 2023·9 cites·21 claims
- 0397US11806322B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 7, 2023·6 cites·26 claims
- 0497US11806321B2Non-linear dosing of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 7, 2023·11 cites·24 claims
- 0596US11839595B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Dec 12, 2023·3 cites·26 claims
- 0695US12029711B1Dosage forms of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Jul 9, 2024·6 cites·30 claims
- 0795US11883375B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jan 30, 2024·2 cites·30 claims
- 0894US12324791B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jun 10, 2025·1 cites·2 claims
- 0990US12295925B2Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted May 13, 2025·0 cites·25 claims
- 1090US12257215B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Mar 25, 2025·0 cites·22 claims
- 1190US12220390B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Feb 11, 2025·0 cites·30 claims
- 1289US2024216305A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1389US2024216306A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1489US2024226037A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1588US12383517B2Dosage forms of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Aug 12, 2025·0 cites·22 claims
- 1688US12263146B2Non-linear dosing of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Apr 1, 2025·0 cites·15 claims
- 1783US2025275932A1Treatment of neurofibromatosis type 1 (nf1) associated plexiform neurofibromas (pn) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1881US2025387356A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1981US2025268850A1Non-linear dosing of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2081US2025387358A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2181US2025387357A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2281US2025387355A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2369US12390430B1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Aug 19, 2025·0 cites·18 claims
Join the waitlist — get patent alerts
Get an alert when Uchenna H. Iloeje files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →